Mushroom extract for liver cancer after TACE
Part of Cancer, Digestive system clinical trials.
This trial is testing if an extract from a medicinal mushroom (Antrodia cinnamomea) can help people with liver cancer who have had a treatment called TACE (chemoembolization). It looks at whether the mushroom extract can improve liver health and recovery after the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 80 years old.
- Your liver function is stable (Child-Pugh class A or B).
- Your bilirubin level is not too high, and your liver enzymes (ALT/AST) are less than twice the normal limit.
- You do not have a blood clot in the main vein of your liver (portal vein).
- Your tumors are not spread throughout the whole liver (diffuse).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (FB-1603) given along with standard TACE procedure for people with liver cancer. It aims to see if the combination is safe and works better than TACE alone.
This trial tests whether a liver-directed treatment called TACE (transarterial chemoembolization) after surgery can help prevent liver cancer from coming back in people with high-risk features.
This trial compares two treatments for liver cancer that cannot be removed by surgery: TACE (a procedure that blocks the tumor's blood supply) plus an oral drug cocktail versus TACE plus standard immunotherapy. The goal is to see which approach works better and is safer.
This trial tests a combination of liver-directed therapy (TACE) with two drugs—bevacizumab (Avastin) and atezolizumab (Tecentriq)—as a first treatment for liver cancer that cannot be removed by surgery. The goal is to see if this approach helps shrink tumors and control the disease longer.
This trial is collecting information on how well a treatment (likely TACE, a procedure to block the tumor's blood supply) works for people with liver cancer that cannot be removed by surgery. It aims to see how safe and effective it is for patients who haven't had treatment before or who have a first recurrence.
This trial tests whether taking icariin soft capsules along with a liver-directed treatment called TACE can help prevent liver cancer from coming back after surgery or ablation. It is for people who have had their tumor removed but still have risk factors that make recurrence more likely.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.